Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
KalVista Pharmaceuticals, Inc. - Common Stock
(NQ:
KALV
)
15.96
+0.14 (+0.88%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 8, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about KalVista Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025
September 04, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2025
August 27, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder
August 21, 2025
FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients.
Via
Benzinga
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
August 11, 2025
Dr. Reid brings 30 years of experience in building biotech companies based on innovative scientific platforms and shaping pipeline and business strategy
From
Metagenomi, Inc.
Via
GlobeNewswire
KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union
August 11, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks
July 25, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
July 15, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
July 14, 2025
Via
Benzinga
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results
July 10, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Meta Platforms To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Tuesday
July 08, 2025
Via
Benzinga
KalVista Pharmaceuticals, Cogent Biosciences, WNS And Other Big Stocks Moving Higher On Monday
July 07, 2025
Via
Benzinga
KalVista Stock Soars Pre-Market On FDA Approval For Drug In Treating Swelling Disorder: Retail’s Elated
July 07, 2025
Ekterly is the first and only oral on-demand treatment for hereditary angioedema, KalVista said, setting it apart from other on-demand treatment options approved in the U.S., which require intravenous...
Via
Stocktwits
KalVista Ends Its Unexpectedly Messy Path To Approval In HAE Treatment
July 07, 2025
The FDA signed off on KalVista Pharmaceuticals' emergency treatment for swelling attacks associated with a rare disease.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
July 07, 2025
Via
Benzinga
FDA Approves KalVista's Ekterly As First Oral On-Demand Treatment For Rare Swelling Disease
July 07, 2025
KalVista's Ekterly, backed by strong trial data, receives FDA approval as the first oral therapy for acute hereditary angioedema attacks in the US.
Via
Benzinga
KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
July 07, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada
June 26, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
How KalVista Pharma Is Taking On A Rare But Deadly Disease
June 20, 2025
The company is working on the first new on-demand treatment for hereditary angioedema in 11 years.
Via
Investor's Business Daily
KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis
June 16, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints
June 13, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025
June 05, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 03, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management
June 02, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
May 29, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings
May 22, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference
April 30, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.